Teva- Pharmaceutical Industries (TEVA) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Air Carbon Clean Climate Climate Change Conservation Emission Energy Efficiency Environment Environmental Environmental Protection Extreme Weather Forest GHG GHG Emissions Green Greenhouse Gas Greenhouse Gas Emission Lifecycle Materials Natural Resources Nature Offset Package Packaging Pandemic Planet Pollutant Raw Materials Renewable Scarcity Scope 1 Scope 3 Soil Superfund Waste Water Water Stress Access Asian Attrition Benefits Black California Consumer Privacy Act Charity Collective Bargaining Community Culture Customer Cyber Cyber Security Cybersecurity Data Privacy Data Security Death Disability Diversity Drug Pricing Employee Employee Engagement Employee Resource Group Employee Training Engagement Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Human Capital Human Resources Incident Inequality Injured Injuries Injury Labor practice Latinx LGBTQ Opioid Overtime Pay Equity Pay for Performance Perquisites Privacy Product Quality Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skilled Skills Social Societal Society Stakeholder Supplier Supply Chain Sustainability-linked Bond Talent Training Union Women Workforce Working Condition Action Plan Anti-corruption Antitrust Assessment Assurance Attorney General Attorneys General Audit Board Evaluation Board Oversight Board Refreshment Bonus Bribery Chronic Classified Classified Board Clawback Commitment Committee Evaluation Controversy Corporate Governance Corporate Purpose Corruption Department of ESG Ethics Executive Compensation Expert External Assurance Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Inequality Innovate Innovation Innovative Investigation Key Performance Indicator Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Materiality Materiality Assessment Mission Oversee Oversight Perquisite Plaintiff Pledging Procurement Purpose Quality Standard R&D Recoup Reputation Reputational Reputational Risk Research and Development Resilient Responsibility Responsible Self-evaluation Shareholder Engagement Shareholder Proposals Special Meeting Strategy Sustainability Sustainable Targets Tax Tax Gross Up Tenure Term Limit Transparency Transparent Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

As described above, Teva held its Annual Meeting on June 23, 2022. The following is a summary of the matters voted on at the meeting.
(1) The shareholders elected to appoint the following persons to the Board, each to serve until Teva’s 2025 annual meeting of shareholders, as follows:

Directors	For	Against	Abstain	Brokers non-vote

Amir Elstein	444,521,760	139,011,657	602,002	110,547,422
Roberto A. Mignone	469,539,322	113,977,054	619,040	110,547,425
Dr. Perry D. Nisen	473,460,959	110,070,839	603,618	110,547,425
Dr. Tal Zaks	475,714,380	107,826,034	595,006	110,547,421

(2) The shareholders approved, on a non-binding advisory basis, the compensation for Teva’s named executive officers listed in the proxy statement for the Annual Meeting, as follows:

For		Against		Abstain		Brokers non-vote

424,554,002		137,783,772		21,797,642		110,547,425

(3) The shareholders approved Teva’s Compensation Policy with respect to the terms of office and employment of Teva’s Executive Officers and Directors as follows.

	For	Against	Abstain	Brokers non-vote

Indicating “YES” for personal interest	9,100,277	2,142,511	120,718	0
Indicating “NO” for personal interest	415,051,270	126,286,322	21,564,100	0
Total	424,151,547	128,428,833	21,684,818	0

(4) The shareholders approved amendments to Teva’s Articles, as follows:

For		Against		Abstain		Brokers non-vote

523,934,723		58,788,742		1,411,956		110,547,420

(5) The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2023 annual meeting of shareholders, as follows:

For		Against		Abstain		Brokers non-vote

667,890,796		21,659,403		1,296,846		0